Related Experiment Video
Updated: Feb 25, 2026
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
Published on: January 7, 2019
Treatment of patients with primary myelofibrosis using dasatinib
1Department of Hematology, the People's Hospital of Jiaozuo City, Jiaozuo, Henan Province, China. cnqinglinsong@126.com.
Objective:
Primary myelofibrosis (PMF) is a chronic clonal myeloproliferative neoplasm. It is associated with a poor prognosis, with a median survival time of approximately five years. Thus far, there are no specific targeted drugs for PMF. In this study, we evaluated the efficacy and safety of dasatinib, a second-generation tyrosine kinase inhibitor, in six PMF patients.
Patients And Methods:
From June 1, 2015 to February 29, 2016, six patients with PMF in our department were enrolled into this trial. The efficacy and safety of 100 mg/d (50 mg twice daily) dasatinib were investigated in these patients.
Results:
For patients who experienced adverse drug events, the dose was reduced to 70 or 50 mg/d, whereas for those who tolerated the drug well, the dosage was increased to 140 mg/d (70 mg twice a day). Of the six patients, two achieved bone marrow histologic remission, five showed symptomatic improvement, and one reached a stable condition. No severe hematological or non-hematological adverse events were observed thus far.
Conclusions:
Dasatinib treatment may be beneficial to patients with PMF and resulted in significant improvements in splenomegaly, clinical symptoms, physical condition, and quality of life. Therefore, we regard it as an effective therapy for PMF.
Insights
Dasatinib, a tyrosine kinase inhibitor, shows promise for treating primary myelofibrosis (PMF). This study found dasatinib improved symptoms and quality of life in PMF patients with manageable side effects.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Primary myelofibrosis (PMF) is a serious chronic cancer of the bone marrow with a poor prognosis.
- Current treatments for PMF lack targeted therapies, highlighting an unmet medical need.
- The median survival for PMF patients is approximately five years.
Purpose of the Study:
- To evaluate the efficacy and safety of dasatinib, a second-generation tyrosine kinase inhibitor, in patients with PMF.
- To assess the impact of dasatinib on clinical symptoms, bone marrow histology, and overall quality of life in PMF.
Main Methods:
- A trial involving six PMF patients was conducted from June 1, 2015, to February 29, 2016.
- Dasatinib was administered at an initial dose of 100 mg/d (50 mg twice daily), with dose adjustments based on tolerance and adverse events.
- Dosage modifications included reductions to 70 or 50 mg/d for adverse events and increases to 140 mg/d for well-tolerated cases.
Main Results:
- Five out of six patients experienced symptomatic improvement.
- Two patients achieved bone marrow histologic remission.
- One patient maintained a stable condition, and no severe adverse events were reported.
Conclusions:
- Dasatinib treatment demonstrated potential benefits for PMF patients.
- Significant improvements were observed in splenomegaly, clinical symptoms, physical condition, and quality of life.
- Dasatinib is considered an effective therapeutic option for primary myelofibrosis.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:56Treatment Resistant Cancers